Aurinia announces FDA acceptance of NDA filing and priority review for voclosporin to treat lupus nephritis

Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple indications, announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for voclosporin, as a potential treatment for lupus nephritis (LN), a serious inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE).